Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

por Trojanec, R, Koudelakova, V, Bouchalova, K, Radova, L, Ondryasova, H, Krejci, E, Megova, M, Cizkova, M, Mlcochova, S, Melichar, B, Hajduch, M
Publicado 2011

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

por Bouchalova, K, Cizkova, M, Trojanec, R, Koudelakova, V, Radova, L, Furstova, J, Melichar, B, Cwiertka, K, Kharaishvili, G, Kolar, Z, Hajduch, M
Publicado 2011

P1648: ANALYSIS OF ANKRD26 GENE 5’UTR VARIANTS IN A COHORT OF CZECH PATIENTS WITH SUSPECTED HEREDITARY HEMATOLOGICAL DISORDER

por Stano Kozubik, K., Trizuljak, J., Vrzalova, Z., Radova, L., Blahakova, I., Stika, J., Smejkal, P., Bergerova, V., Hynst, J., Pospisilova, S., Doubek, M.
Publicado 2022

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia

por Malcikova, J, Stano-Kozubik, K, Tichy, B, Kantorova, B, Pavlova, S, Tom, N, Radova, L, Smardova, J, Pardy, F, Doubek, M, Brychtova, Y, Mraz, M, Plevova, K, Diviskova, E, Oltova, A, Mayer, J, Pospisilova, S, Trbusek, M
Publicado 2015

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

por Kubesova, B, Pavlova, S, Malcikova, J, Kabathova, J, Radova, L, Tom, N, Tichy, B, Plevova, K, Kantorova, B, Fiedorova, K, Slavikova, M, Bystry, V, Kissova, J, Gisslinger, B, Gisslinger, H, Penka, M, Mayer, J, Kralovics, R, Pospisilova, S, Doubek, M
Publicado 2018